Atopic Dermatitis

In the ARCADIA LTE, nemolizumab maintained significant and progressive improvements in skin and itch outcomes for up to 104 weeks.

The episode underscores the clinical value of listening to patient advocates who bring firsthand understanding of disease impact.

Mobile app SkinTracker enhances atopic dermatitis care through remote assessments, proving effective and convenient for patients while saving costs.

Panelists discuss how the current topical standard of care has evolved from traditional topical steroids developed in the 1960s to include newer nonsteroidal options like ruxolitinib (Janus kinase [JAK] inhibitor), roflumilast (phosphodiesterase-4 [PDE4] inhibitor), and tapinarof (aryl hydrocarbon receptor agonist), with steroids now serving as bridge treatments rather than long-term maintenance therapy.

Panelists discuss how atopic dermatitis presents differently across pediatric age groups. Infants show lesions on cheeks and extensor surfaces, whereas older children develop more typical flexural patterns. They also discuss how the condition significantly impacts the quality of life for patients and caregivers through sleep disruption, school performance issues, and ongoing parental stress.

A novel 4% glycyrrhetinic acid scalp gel shows rapid relief for mild to moderate seborrheic dermatitis, enhancing treatment options with herbal ingredients.

During a Case-Based Roundtable event, Naiem Issa, MD, PhD, guided colleagues through 3 complex atopic dermatitis cases, highlighting how modern topicals can deliver rapid and durable control across age groups.

Radiation dermatitis significantly affects breast cancer patients, impacting quality of life and treatment. Discover effective prevention and management strategies.

The FDA has approved roflumilast 0.05% cream for atopic dermatitis in children aged 2 years and older, extending its use to a critical pediatric population.

Sitryx Therapeutics advances SYX-5219 for moderate to severe AD, aiming for a first-in-class oral treatment with potential for lasting disease remission.

The approval represents the sixth FDA authorization for roflumilast since 2022.

Patient advocate Danielle Jonas shares her journey with atopic dermatitis, emphasizing the importance of trusted products and clinician support during Eczema Awareness Month.

Bambusa Therapeutics reveals promising phase I trial results for BBT001, targeting atopic dermatitis with dual-action bispecific antibodies.

TRIV-509 is a dual KLK5/7 inhibitor that aims to address barrier dysfunction, inflammation, and itch in moderate to severe AD.

Kara Mudd, PA-C, shares vital insights on atopic dermatitis, rosacea, and contact dermatitis from Maui Derm NP+PA Fall 2025, enhancing clinical practice.

Walter Liszewski, MD, shares innovative and personalized treatment strategies for managing atopic and contact dermatitis at Maui Derm NP+PA Fall 2025.

Discover the latest advancements in pediatric dermatology and atopic dermatitis treatments from Maui Derm NP+PA Fall 2025, featuring expert insights and emerging therapies.

Rebecca Smith, MD, recently led a Dermatology Times Case-Based Roundtable event on complex cases in atopic dermatitis.

Panelists discuss how atopic dermatitis exhibits tremendous heterogeneity in clinical presentation, disease course, symptom variability, environmental triggers, and underlying immunologic and genetic factors that contribute to the challenge of developing one-size-fits-all treatments.

Panelists discuss how despite recent therapeutic advances in atopic dermatitis treatment, significant unmet needs remain including partial responses, lack of long-term stable control, and the need for broader patient response rates and deeper clearance levels.

Berdazimer shows promise for treating MC in pediatric patients, even in those with a history of atopic dermatitis, according to a poster at Maui Derm NP+PA Fall.

Phase 1a results showing STAR-0310’s half-life of up to 68 days, durable cytokine inhibition, and a favorable safety profile will be presented in full at EADV 2025.

Evidence presented at EADV supports upadacitinib’s long-term use in atopic dermatitis and other inflammatory conditions.

At week 16, up to 61% mean EASI reduction was observed in high-dose patients versus 31% in placebo.

Treatment with APG777 led to a significant 71.0% reduction in EASI scores from baseline to week 16, compared to a 33.8% reduction with placebo, according to data presented at EADV 2025.